YungShin Global Holding Corporation (3705.TW)
TWD 65.0
(-1.07%)
TWD 65.0
(-1.07%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -247.5 Million TWD | -96.26% |
| 2022 | -126.1 Million TWD | -108.18% |
| 2021 | 1.54 Billion TWD | -24.56% |
| 2020 | 2.04 Billion TWD | 1.96% |
| 2019 | 2 Billion TWD | -6.52% |
| 2018 | 2.14 Billion TWD | 22.9% |
| 2017 | 1.74 Billion TWD | 39.49% |
| 2016 | 1.25 Billion TWD | 426.58% |
| 2015 | 237.55 Million TWD | 192.28% |
| 2014 | -257.42 Million TWD | -97.84% |
| 2013 | -130.11 Million TWD | -1453.28% |
| 2012 | -8.37 Million TWD | 92.22% |
| 2011 | -107.62 Million TWD | 82.45% |
| 2010 | -613.1 Million TWD | -21.82% |
| 2009 | -503.28 Million TWD | -66.52% |
| 2008 | -302.24 Million TWD | 0.0% |
| 2006 | -575.64 Million TWD | -91.44% |
| 2005 | -300.68 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -641.91 Million TWD | -46.18% |
| 2024 Q1 | -439.12 Million TWD | -77.42% |
| 2023 Q2 | -699.55 Million TWD | -67.09% |
| 2023 Q3 | -54.32 Million TWD | 92.23% |
| 2023 Q1 | -418.66 Million TWD | -231.99% |
| 2023 Q4 | -247.5 Million TWD | -355.58% |
| 2023 FY | -247.5 Million TWD | -96.26% |
| 2022 Q1 | 1.27 Billion TWD | -17.4% |
| 2022 Q4 | -126.1 Million TWD | -134.26% |
| 2022 Q3 | 368.13 Million TWD | -21.9% |
| 2022 Q2 | 471.35 Million TWD | -62.99% |
| 2022 FY | -126.1 Million TWD | -108.18% |
| 2021 FY | 1.54 Billion TWD | -24.56% |
| 2021 Q4 | 1.54 Billion TWD | -20.27% |
| 2021 Q3 | 1.93 Billion TWD | 31.05% |
| 2021 Q2 | 1.47 Billion TWD | -18.6% |
| 2021 Q1 | 1.81 Billion TWD | -11.3% |
| 2020 Q1 | 1.98 Billion TWD | -1.2% |
| 2020 FY | 2.04 Billion TWD | 1.96% |
| 2020 Q2 | 2 Billion TWD | 1.24% |
| 2020 Q3 | 2.6 Billion TWD | 29.86% |
| 2020 Q4 | 2.04 Billion TWD | -21.51% |
| 2019 FY | 2 Billion TWD | -6.52% |
| 2019 Q2 | 2.09 Billion TWD | -7.31% |
| 2019 Q3 | 2.57 Billion TWD | 23.15% |
| 2019 Q4 | 2 Billion TWD | -22.27% |
| 2019 Q1 | 2.25 Billion TWD | 5.37% |
| 2018 Q2 | 1.62 Billion TWD | 0.35% |
| 2018 FY | 2.14 Billion TWD | 22.9% |
| 2018 Q3 | 2.45 Billion TWD | 50.95% |
| 2018 Q4 | 2.14 Billion TWD | -12.76% |
| 2018 Q1 | 1.62 Billion TWD | -7.01% |
| 2017 Q3 | 1.97 Billion TWD | 28.1% |
| 2017 Q2 | 1.54 Billion TWD | -3.97% |
| 2017 Q1 | 1.6 Billion TWD | 28.4% |
| 2017 FY | 1.74 Billion TWD | 39.49% |
| 2017 Q4 | 1.74 Billion TWD | -11.68% |
| 2016 FY | 1.25 Billion TWD | 426.58% |
| 2016 Q2 | 700.94 Million TWD | 196.11% |
| 2016 Q4 | 1.25 Billion TWD | -7.37% |
| 2016 Q1 | 236.71 Million TWD | -0.35% |
| 2016 Q3 | 1.35 Billion TWD | 92.66% |
| 2015 Q3 | 149.99 Million TWD | 133.92% |
| 2015 FY | 237.55 Million TWD | 192.28% |
| 2015 Q4 | 237.55 Million TWD | 58.37% |
| 2015 Q2 | -442.18 Million TWD | -89.39% |
| 2015 Q1 | -233.48 Million TWD | 9.3% |
| 2014 Q3 | -3.07 Million TWD | 99.38% |
| 2014 Q2 | -496.65 Million TWD | -71.95% |
| 2014 Q1 | -288.84 Million TWD | -121.99% |
| 2014 FY | -257.42 Million TWD | -97.84% |
| 2014 Q4 | -257.42 Million TWD | -8260.77% |
| 2013 Q1 | -157.51 Million TWD | -1780.37% |
| 2013 Q2 | -311.34 Million TWD | -97.66% |
| 2013 Q4 | -130.11 Million TWD | -163.72% |
| 2013 Q3 | 204.19 Million TWD | 165.59% |
| 2013 FY | -130.11 Million TWD | -1453.28% |
| 2012 Q2 | -61 Million TWD | 24.75% |
| 2012 Q3 | 254.82 Million TWD | 517.68% |
| 2012 Q4 | -8.37 Million TWD | -103.29% |
| 2012 FY | -8.37 Million TWD | 92.22% |
| 2012 Q1 | -81.07 Million TWD | 24.67% |
| 2011 Q3 | -105.03 Million TWD | 84.8% |
| 2011 FY | -107.62 Million TWD | 82.45% |
| 2011 Q1 | -15.93 Million TWD | 97.4% |
| 2011 Q2 | -690.88 Million TWD | -4235.39% |
| 2011 Q4 | -107.62 Million TWD | -2.46% |
| 2010 FY | -613.1 Million TWD | -21.82% |
| 2010 Q4 | -613.1 Million TWD | 0.0% |
| 2009 FY | -503.28 Million TWD | -66.52% |
| 2008 FY | -302.24 Million TWD | 0.0% |
| 2006 FY | -575.64 Million TWD | -91.44% |
| 2005 FY | -300.68 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Grape King Bio Ltd | -4.62 Billion TWD | 94.65% |
| Standard Chem & Pharm CO., LTD. | -954.74 Million TWD | 74.077% |
| Maywufa Company Ltd. | 264.18 Million TWD | 193.685% |
| ScinoPharm Taiwan, Ltd. | -3.32 Billion TWD | 92.546% |
| Lotus Pharmaceutical Co., Ltd. | 9.81 Billion TWD | 102.522% |
| LIWANLI Innovation Co., Ltd. | -244.02 Million TWD | -1.425% |
| PhytoHealth Corporation | -34.64 Million TWD | -614.474% |
| SCI Pharmtech, Inc. | 100.41 Million TWD | 346.473% |
| Formosa Laboratories, Inc. | 2.53 Billion TWD | 109.75% |
| PharmaEssentia Corporation | -18.46 Billion TWD | 98.66% |
| Bora Pharmaceuticals Co., LTD. | 1.95 Billion TWD | 112.65% |